Patient characteristics
| Total population N=970 | Comorbidity group N=482 | Self-assessment group N=488 | |
|---|---|---|---|
| Age, years; mean±SD | 58±11 | 58±11 | 57±11 |
| Sex, female; n (%) | 767±(79.1) | 383±(79.5) | 384±(78.7) |
| Body Mass Index; mean±SD | 25.2±4.8 | 25.2±4.8 | 25.2±4.9 |
| Educational level, % university | 285±(29.4) | 153±(31.7) | 132±(27.0) |
| Disease duration, years; median (Q1; Q3) | 11.10 (6.22; 19.08) | 11.04 (6.42; 18.47) | 11.21 (5.74; 19.38) |
| Positive RF or anti-CCP; n (%) | 806 (83.7) | 408 (85.4) | 398 (82.1) |
| Erosive RA; n (%) | 703 (73.5) | 353 (74.3) | 350 (72.6) |
| DAS28 score; mean±SD | 3.09±1.28 | 2.98±1.23 | 3.20±1.32 |
| mHAQ score; mean±SD | 0.4±0.5 | 0.4±0.4 | 0.4±0.5 |
| RAID mean±SD | 3.0±2.0 | 2.9±2.0 | 3.1±2.1 |
| History of RA-related definite surgeries, n (%)† | 290.0 (30) | 148 (30.8) | 142 (29.2) |
| Number of prior DMARD therapies; mean±SD | 2.62±1.58 | 2.62±1.53 | 2.61±1.62 |
| Current MTX; n (%) | 677 (70.5) | 326 (68.3) | 351 (72.7) |
| Number of biotherapies; mean±SD | 1.50±1.39 | 1.55±1.39 | 1.46±1.39 |
| Current biotherapy, n (%) | 725 (74.7) | 364 (75.5) | 361 (73.9) |
| Current corticosteroid intake | |||
| Patients, n (%) | 367 (38) | 170 (35) | 197 (40) |
| Dose, mg/kg; mean±SD | 2.15±4.39 | 2.11±5.34 | 2.18±3.19 |
| Myocardial infarction; n (%) | 14 (1.5) | 9 (1.9) | 5 (1.1) |
| Angina pectoris; n (%) | 11 (1.2) | 3 (0.6) | 8 (1.7) |
| Stroke; n (%) | 18 (1.9) | 9 (1.9) | 9 (2.0) |
| Peripheral arterial disease; n (%) | 11 (1.2) | 5 (1.0) | 6 (1.3) |
| Current smoking; n (%) | 157 (16.7) | 66 (13.8) | 91 (19.8) |
| Diabetes; n (%) | 56 (6.0) | 29 (6.0) | 27 (5.9) |
| Hypertension; n (%) | 284 (30.2) | 147 (30.6) | 137 (29.8) |
| Lipid-lowering therapy; n (%) | 186 (19.8) | 94 (19.6) | 92 (20.0) |
| Prior breast cancer; n (%) | 29 (3.9) | 16 (4.2) | 13 (3.6) |
| Prior skin cancer; n (%) | 34 (3.6) | 18 (3.8) | 16 (3.5) |
| Prior fracture; n (%) | 299/939 (31.8) | 152/480 (31.7) | 147/459 (32.0) |
| Osteoporosis treatment; n (%) | 155/939 (16.5) | 78/480 (16.3) | 77/459 (16.8) |
Data presented are either mean±SD, number and (percentage), median and (tertile Q1–Q3).
†‘Definite’ RA-related surgery was defined as either total articular replacement or resection arthrodesis of the metatarsophalangeal joint.
anti-CCP, anticyclic citrullinated peptide antibodies; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; mHAQ, modified Health Assessment Questionnaire;58 MTX, methotrexate; RA, rheumatoid arthritis; RAID, Rheumatoid Arthritis Impact Disease;59 RF, rheumatoid factor.